200 related articles for article (PubMed ID: 35713127)
21. Surface Engineered Dendrimers: A Potential Nanocarrier for the Effective Management of Glioblastoma Multiforme.
Sahoo RK; Gupta T; Batheja S; Goyal AK; Gupta U
Curr Drug Metab; 2022; 23(9):708-722. PubMed ID: 35713127
[TBL] [Abstract][Full Text] [Related]
22. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
23. Potential of Nanocarrier-Associated Approaches for Better Therapeutic Intervention in the Management of Glioblastoma.
Vikram ; Kumar S; Ali J; Baboota S
Assay Drug Dev Technol; 2024; 22(2):73-85. PubMed ID: 38193798
[No Abstract] [Full Text] [Related]
24. Targeting brain tumors with innovative nanocarriers: bridging the gap through the blood-brain barrier.
Wadhwa K; Chauhan P; Kumar S; Pahwa R; Verma R; Goyal R; Singh G; Sharma A; Rao N; Kaushik D
Oncol Res; 2024; 32(5):877-897. PubMed ID: 38686045
[TBL] [Abstract][Full Text] [Related]
25. Recent Advances in the Use of Lipid-Based Nanoparticles Against Glioblastoma Multiforme.
Ortega-Berlanga B; Gonzalez C; Navarro-Tovar G
Arch Immunol Ther Exp (Warsz); 2021 Mar; 69(1):8. PubMed ID: 33772646
[TBL] [Abstract][Full Text] [Related]
26. Amphetamine decorated cationic lipid nanoparticles cross the blood-brain barrier: therapeutic promise for combating glioblastoma.
Saha S; Yakati V; Shankar G; Jaggarapu MMCS; Moku G; Madhusudana K; Banerjee R; Ramkrishna S; Srinivas R; Chaudhuri A
J Mater Chem B; 2020 May; 8(19):4318-4330. PubMed ID: 32330214
[TBL] [Abstract][Full Text] [Related]
27. An Evaluation of CXCR4 Targeting with PAMAM Dendrimer Conjugates for Oncologic Applications.
Lesniak WG; Azad BB; Chatterjee S; Lisok A; Pomper MG
Pharmaceutics; 2022 Mar; 14(3):. PubMed ID: 35336029
[TBL] [Abstract][Full Text] [Related]
28. Glycosylation of PAMAM dendrimers significantly improves tumor macrophage targeting and specificity in glioblastoma.
Sharma R; Liaw K; Sharma A; Jimenez A; Chang M; Salazar S; Amlani I; Kannan S; Kannan RM
J Control Release; 2021 Sep; 337():179-192. PubMed ID: 34274384
[TBL] [Abstract][Full Text] [Related]
29. Dendrimer-Mediated Targeted Delivery of Rapamycin to Tumor-Associated Macrophages Improves Systemic Treatment of Glioblastoma.
Sharma A; Liaw K; Sharma R; Spriggs T; Appiani La Rosa S; Kannan S; Kannan RM
Biomacromolecules; 2020 Dec; 21(12):5148-5161. PubMed ID: 33112134
[TBL] [Abstract][Full Text] [Related]
30. Dual functional nanoparticles efficiently across the blood-brain barrier to combat glioblastoma
Jin Z; Piao L; Sun G; Lv C; Jing Y; Jin R
J Drug Target; 2021 Mar; 29(3):323-335. PubMed ID: 33108906
[TBL] [Abstract][Full Text] [Related]
31. Blood-Brain Barrier Disruption in Neuro-Oncology: Strategies, Failures, and Challenges to Overcome.
Karmur BS; Philteos J; Abbasian A; Zacharia BE; Lipsman N; Levin V; Grossman S; Mansouri A
Front Oncol; 2020; 10():563840. PubMed ID: 33072591
[TBL] [Abstract][Full Text] [Related]
32. In vivo Glioblastoma Therapy Using Targeted Liposomal Cisplatin.
Ashrafzadeh MS; Akbarzadeh A; Heydarinasab A; Ardjmand M
Int J Nanomedicine; 2020; 15():7035-7049. PubMed ID: 33061366
[TBL] [Abstract][Full Text] [Related]
33. Targeting Mitochondria in Tumor-Associated Macrophages using a Dendrimer-Conjugated TSPO Ligand that Stimulates Antitumor Signaling in Glioblastoma.
Sharma A; Liaw K; Sharma R; Thomas AG; Slusher BS; Kannan S; Kannan RM
Biomacromolecules; 2020 Sep; 21(9):3909-3922. PubMed ID: 32786523
[TBL] [Abstract][Full Text] [Related]
34. Improved biocompatibility of surface functionalized dendrimer-entrapped gold nanoparticles.
Shi X; Wang S; Sun H; Baker JR
Soft Matter; 2006 Dec; 3(1):71-74. PubMed ID: 32680194
[TBL] [Abstract][Full Text] [Related]
35. Treatment and surgical factors associated with longer-term glioblastoma survival: a National Cancer Database study.
Malay S; Somasundaram E; Patil N; Buerki R; Sloan A; Barnholtz-Sloan JS
Neurooncol Adv; 2020 Jul; 2(Suppl 1):1-10. PubMed ID: 32642726
[TBL] [Abstract][Full Text] [Related]
36. Celecoxib substituted biotinylated poly(amidoamine) G3 dendrimer as potential treatment for temozolomide resistant glioma therapy and anti-nematode agent.
Uram Ł; Markowicz J; Misiorek M; Filipowicz-Rachwał A; Wołowiec S; Wałajtys-Rode E
Eur J Pharm Sci; 2020 Sep; 152():105439. PubMed ID: 32615261
[TBL] [Abstract][Full Text] [Related]
37. iRGD and TGN co-modified PAMAM for multi-targeted delivery of ATO to gliomas.
Shi X; Ma R; Lu Y; Cheng Y; Fan X; Zou J; Zheng H; Li F; Piao JG
Biochem Biophys Res Commun; 2020 Jun; 527(1):117-123. PubMed ID: 32446354
[TBL] [Abstract][Full Text] [Related]
38. PEGylated Dendrimer Mediated Delivery of Bortezomib: Drug Conjugation versus Encapsulation.
Sahoo RK; Gothwal A; Rani S; Nakhate KT; Ajazuddin ; Gupta U
Int J Pharm; 2020 Jun; 584():119389. PubMed ID: 32380027
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
